40 citations
,
May 2010 in “Australasian Journal of Dermatology” This study suggests that chronic telogen effluvium may be due to a reduction in the variance of anagen duration, resulting in recurrent hair shedding with minimal long-term hair volume loss.
32 citations
,
July 2021 in “Journal of The American Academy of Dermatology” This study found that acute telogen effluvium after COVID-19 typically began about 1.5 months post-infection and resolved sooner than typical cases, with most resolving in under two months.
July 2025 in “Clinical and Experimental Dermatology” This study concludes that in men, telogen effluvium (TE) precedes androgenetic alopecia (AGA), with anagen shortening occurring before follicle miniaturization.
4 citations
,
April 2016 in “Experimental Dermatology” This commentary discusses the mechanisms of progression and potential regrowth in androgenetic alopecia, indicating that the initiation of anagen in kenogen follicles is more critical for hair density improvement than reversing follicle miniaturization.
November 2006 in “Yafteh” This study found that an herbal drug reduced the duration of telogen effluvium more effectively than minoxidil in patients.